scholarly journals Smart Human-Serum-Albumin-As2O3Nanodrug with Self-Amplified Folate Receptor-Targeting Ability for Chronic Myeloid Leukemia Treatment

2017 ◽  
Vol 129 (36) ◽  
pp. 10985-10989 ◽  
Author(s):  
Yongbo Peng ◽  
Zilong Zhao ◽  
Teng Liu ◽  
Xiong Li ◽  
Xiaoxiao Hu ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Human Serum Albumin ◽  
Serum Albumin ◽  
Human Serum ◽  
Myeloid Leukemia ◽  
Folate Receptor ◽  
Receptor Targeting ◽  
Leukemia Treatment ◽  
Targeting Ability ◽  
Folate Receptor Targeting

scholarly journals Smart Human-Serum-Albumin-As2O3Nanodrug with Self-Amplified Folate Receptor-Targeting Ability for Chronic Myeloid Leukemia Treatment

2017 ◽  
Vol 56 (36) ◽  
pp. 10845-10849 ◽  
Author(s):  
Yongbo Peng ◽  
Zilong Zhao ◽  
Teng Liu ◽  
Xiong Li ◽  
Xiaoxiao Hu ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Human Serum Albumin ◽  
Serum Albumin ◽  
Human Serum ◽  
Myeloid Leukemia ◽  
Folate Receptor ◽  
Receptor Targeting ◽  
Leukemia Treatment ◽  
Targeting Ability ◽  
Folate Receptor Targeting

An effective and safe treatment strategy for rheumatoid arthritis based on human serum albumin and Kolliphor® HS 15

Nanomedicine ◽  
2019 ◽  
Vol 14 (16) ◽  
pp. 2169-2187 ◽  
Author(s):  
Ting Gong ◽  
Pei Zhang ◽  
Caifeng Deng ◽  
Yu Xiao ◽  
Tao Gong ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Human Serum Albumin ◽  
Serum Albumin ◽  
Human Serum ◽  
Therapeutic Strategy ◽  
Inflammatory Cell ◽  
In Vivo Studies ◽  
Targeting Ability

Aim: We aimed to construct human serum albumin-Kolliphor® HS 15 nanoparticles (HSA-HS15 NPs) to overcome the limitations in targeted therapy for rheumatoid arthritis (RA) and enhance the safety of drug-loaded HSA NPs. Methodology: Celastrol (CLT)-loaded HSA-HS15 NPs were prepared and the properties were adequately investigated; the treatment effect were evaluated in RA rats; in vitro and in vivo studies were performed to explain the mechanism. Results: CLT-HSA-HS15 NPs had remarkable treatment ability and enhanced safety in the treatment of RA compared with free CLT and CLT-HSA NPs. Conclusion: HSA-HS15 NPs could be a safe and efficient therapeutic strategy for the treatment of RA, because of the inflammatory targeting ability of albumin, the added HS15 and ELVIS effect (extravasation through leaky vasculature followed by inflammatory cell-mediated sequestration) of nanoparticles.

Coomassie Bright Blue-Conjugated Human Serum Albumin Nanoparticles as a Tumor-Selective Weapon for Leukemia Therapy

2019 ◽  
Vol 11 (12) ◽  
pp. 1651-1660
Author(s):  
Lingfeng Xu ◽  
Zhuoxuan Lu ◽  
Guang-Hong Tan ◽  
Feng-Ying Huang ◽  
Rong Cao ◽  
...  
Keyword(s):  
Human Serum Albumin ◽  
Serum Albumin ◽  
Human Serum ◽  
Blood Compatibility ◽  
Leukemia Cell ◽  
Leukemia Cells ◽  
Mouse Serum ◽  
G1 Arrest ◽  
Normal Cells ◽  
Leukemia Treatment

Leukemia is a group of blood cancers which seriously endangers the health of many people, especially children and adolescents. Although some drugs have been developed to treat leukemia, these drugs always have harmful side effects, which seriously affect the quality of life of patients. Therefore, the development of a special drug which damages only leukemia cells and does not harm normal cells remains a challenge. In a previous study, we developed a novel nanomedicine, Cy5.5MSA-G250, which selectively kills fast-growing tumor cells without harming normal cells. Based on our previous work, we prepared Cy5.5-HSA-G250 nanoparticles (CHGNPs) by replacing mouse serum albumin (MSA) with low immunogenic human serum albumin (HSA), and then applied this nanomaterial in leukemia treatment. Under physiological conditions, the CHGNPs exhibited good dispersion and stability, and hemolytic experiments showed that this material has excellent blood compatibility. The cell endocytosis of CHGNPs was obviously inhibited after treatment with nystatin and chlorpromazine, implying that caveolae-mediated endocytosis and clathrin-mediated endocytosis are involved in the cellular uptake of CHGNPs. Cytotoxicity and apoptosis assays revealed that the CHGNPs severely inhibited leukemia cell proliferation and induced leukemia cell apoptosis but did not affect normal cells. The selective up-regulation of tumor suppressor protein P27 and inducement of G1 arrest in leukemia cells may be the main mechanisms for CHGNPs' selective cytotoxicity. Owing to these advantages of CHGNPs, we believe that CHGNPs can be used as a potential leukemia drug for clinical treatment.

Flexible MoS2 -Embedded Human Serum Albumin Hollow Nanocapsules with Long Circulation Times and High Targeting Ability for Efficient Tumor Ablation

2018 ◽  
Vol 28 (45) ◽  
pp. 1804081 ◽  
Author(s):  
Chaoli Xu ◽  
Zhaogang Teng ◽  
Yunlei Zhang ◽  
Lihui Yuwen ◽  
Qi Zhang ◽  
...  
Keyword(s):  
Human Serum Albumin ◽  
Serum Albumin ◽  
Human Serum ◽  
Tumor Ablation ◽  
Targeting Ability

Designing biotin-human serum albumin nanoparticles to enhance the targeting ability of binuclear ruthenium(III) compound

2021 ◽  
Vol 215 ◽  
pp. 111318
Author(s):  
Ming Jiang ◽  
Shanhe Li ◽  
Junmiao Wu ◽  
Wenjuan Li ◽  
Xiao-an Wen ◽  
...  
Keyword(s):  
Human Serum Albumin ◽  
Serum Albumin ◽  
Human Serum ◽  
Albumin Nanoparticles ◽  
Targeting Ability

The Effect of Human Serum Albumin and Mercurial Diuretics on Ascites in Patients With Hepatic Cirrhosis

1950 ◽  
Vol 16 (2) ◽  
pp. 455-465 ◽  
Author(s):  
W. Paul Havens ◽  
Lewis W. Bluemle
Keyword(s):  
Human Serum Albumin ◽  
Serum Albumin ◽  
Human Serum ◽  
Hepatic Cirrhosis

II. Lokalisation der Placenta mit 113Inm- Human-Serum-Albumin

1969 ◽  
Vol 08 (01) ◽  
pp. 15-21 ◽  
Author(s):  
K. E. Scheer ◽  
J. Heep ◽  
W. Maier-Borst ◽  
W. J. Lorenz ◽  
H. Sinn ◽  
...  
Keyword(s):  
Human Serum Albumin ◽  
Serum Albumin ◽  
Human Serum ◽  
Vena Cava ◽  
Placenta Praevia ◽  
Wird Eine

ZusammenfassungNach tierexperimentellen Voruntersuchungen wurde die Placentographie mit trägerfreiem 113Inm -HSA als klinische Methode eingeführt. Vor Amniocentesen und bei Verdacht auf Placenta praevia werden Placentographien geschrieben. Den Schwangeren wird eine Aktivität von 500 μCi in die Cubitalvene injiziert. Die der Aktivität entsprechende Indiummenge ist kleiner als 0,1 ng. Die fetale Strahlenbelastung liegt unter lOmrad. Bei Anwendung von 113Inm-HSA entfällt eine Blockade der mütterlichen und fetalen Schilddrüsen. Die genaue Abgrenzung einer Placenta praevia wird nicht durch eine Blasenaktivität beeinträchtigt.Es wurden bisher 19 Placentalokalisationen durchgeführt. In allen Fällen konnte der Placentasitz eindeutig festgestellt werden. Bedingt durch die lange Liegezeit beim Aufnehmen eines Szintigramms kam es in zwei Fällen zu einem Vena-Cava-Kompressions-Syndrom. Zur Verhinderung dieser klinischen Zwischenfälle werden inzwischen Placentographien mit der Anger-Kamera aufgenommen. Mit Hilfe des divergierenden Kollimators konnte der gesamte Abdominalbereich erfaßt werden. Die Aufnahmezeit konnte auf 7 — 10 Minuten verkürzt werden. Die intravenöse injizierte Aktivität betrug bei dieser Methode ebenfalls 500 μCi. Der diagnostische Aussagewert der Kamerabilder ist szintigraphischen Aufnahmen gleichwertig.

Sign in / Sign up

Export Citation Format

Share Document